The association between reduced GFR and hearing loss: a cross-sectional population-based study

Eswari Vilayur, Bamini Gopinath, David C. Harris, George Burlutsky, Catherine M. McMahon, Paul Mitchell

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Chronic kidney disease (CKD) has long been associated with hearing loss in certain syndromes. Reported evidence to date has come from only small observational studies. We present the first community-based study to show an association between nonsyndromal CKD and hearing loss. Study Design: Cross-sectional population-based study to examine the relationship between CKD and age-related hearing loss. Setting & Participants: The Blue Mountains Hearing Study is a survey of age-related hearing loss conducted in 1997-2004; a total of 2,564 participants had audiometric testing and complete renal data. Predictor or Factor: Moderate CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Outcomes: Bilateral hearing loss, defined as average pure-tone threshold >25 dB for measurements at frequencies of 0.5, 1.0, 2.0, and 4.0 kHz. Measurements: Baseline biochemistry tests, including serum creatinine, were performed. Pure-tone audiometry was performed in sound-treated booths. Results: Moderate CKD was present in 513 of 2,564 participants. Of persons with moderate CKD, 279 (54.4%) had measured hearing loss compared with 581 (28.3%) with eGFR <60 mL/min/1.73 m2. Moderate CKD was independently associated with hearing loss (OR, 1.43; 95% CI, 1.10-1.84; P = 0.006) after adjusting for age; sex; noise exposure; education; diabetes, hypertension, and stroke histories; and smoking. Participants with eGFR <45 mL/min/1.73 m2 had the highest prevalence of hearing loss (73%) compared with those with eGFR <90 mL/min/1.73 m2 (19%; multivariate adjusted OR, 2.4 [95% CI, 1.3-4.5]). Analyses were repeated after excluding participants reporting furosemide use (a known ototoxic agent); the association between moderate CKD and hearing loss remained significant (multivariate adjusted OR, 1.40 [95% CI, 1.08-1.83]; P = 0.01). Limitations: The present study is not longitudinal and does not permit causal inference from the observed associations. Conclusions: Moderate CKD per se was associated independently with hearing loss. Recognizing this link could lead to earlier hearing assessment with appropriate interventions to preserve the hearing of patients with CKD. Am J Kidney Dis 00:00-00

LanguageEnglish
Pages661-669
Number of pages9
JournalAmerican Journal of Kidney Diseases
Volume56
Issue number4
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Chronic Renal Insufficiency
Hearing Loss
Population
Glomerular Filtration Rate
Hearing
Pure-Tone Audiometry
Kidney
Furosemide
Biochemistry
Observational Studies
Noise
Creatinine
Cross-Sectional Studies
Smoking
Stroke
Hypertension
Education
Serum

Cite this

Vilayur, Eswari ; Gopinath, Bamini ; Harris, David C. ; Burlutsky, George ; McMahon, Catherine M. ; Mitchell, Paul. / The association between reduced GFR and hearing loss : a cross-sectional population-based study. In: American Journal of Kidney Diseases. 2010 ; Vol. 56, No. 4. pp. 661-669.
@article{1448b8bf5b4e437aa549b4bbab9cffca,
title = "The association between reduced GFR and hearing loss: a cross-sectional population-based study",
abstract = "Background: Chronic kidney disease (CKD) has long been associated with hearing loss in certain syndromes. Reported evidence to date has come from only small observational studies. We present the first community-based study to show an association between nonsyndromal CKD and hearing loss. Study Design: Cross-sectional population-based study to examine the relationship between CKD and age-related hearing loss. Setting & Participants: The Blue Mountains Hearing Study is a survey of age-related hearing loss conducted in 1997-2004; a total of 2,564 participants had audiometric testing and complete renal data. Predictor or Factor: Moderate CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Outcomes: Bilateral hearing loss, defined as average pure-tone threshold >25 dB for measurements at frequencies of 0.5, 1.0, 2.0, and 4.0 kHz. Measurements: Baseline biochemistry tests, including serum creatinine, were performed. Pure-tone audiometry was performed in sound-treated booths. Results: Moderate CKD was present in 513 of 2,564 participants. Of persons with moderate CKD, 279 (54.4{\%}) had measured hearing loss compared with 581 (28.3{\%}) with eGFR <60 mL/min/1.73 m2. Moderate CKD was independently associated with hearing loss (OR, 1.43; 95{\%} CI, 1.10-1.84; P = 0.006) after adjusting for age; sex; noise exposure; education; diabetes, hypertension, and stroke histories; and smoking. Participants with eGFR <45 mL/min/1.73 m2 had the highest prevalence of hearing loss (73{\%}) compared with those with eGFR <90 mL/min/1.73 m2 (19{\%}; multivariate adjusted OR, 2.4 [95{\%} CI, 1.3-4.5]). Analyses were repeated after excluding participants reporting furosemide use (a known ototoxic agent); the association between moderate CKD and hearing loss remained significant (multivariate adjusted OR, 1.40 [95{\%} CI, 1.08-1.83]; P = 0.01). Limitations: The present study is not longitudinal and does not permit causal inference from the observed associations. Conclusions: Moderate CKD per se was associated independently with hearing loss. Recognizing this link could lead to earlier hearing assessment with appropriate interventions to preserve the hearing of patients with CKD. Am J Kidney Dis 00:00-00",
author = "Eswari Vilayur and Bamini Gopinath and Harris, {David C.} and George Burlutsky and McMahon, {Catherine M.} and Paul Mitchell",
year = "2010",
month = "10",
doi = "10.1053/j.ajkd.2010.05.015",
language = "English",
volume = "56",
pages = "661--669",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "4",

}

The association between reduced GFR and hearing loss : a cross-sectional population-based study. / Vilayur, Eswari; Gopinath, Bamini; Harris, David C.; Burlutsky, George; McMahon, Catherine M.; Mitchell, Paul.

In: American Journal of Kidney Diseases, Vol. 56, No. 4, 10.2010, p. 661-669.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The association between reduced GFR and hearing loss

T2 - American Journal of Kidney Diseases

AU - Vilayur, Eswari

AU - Gopinath, Bamini

AU - Harris, David C.

AU - Burlutsky, George

AU - McMahon, Catherine M.

AU - Mitchell, Paul

PY - 2010/10

Y1 - 2010/10

N2 - Background: Chronic kidney disease (CKD) has long been associated with hearing loss in certain syndromes. Reported evidence to date has come from only small observational studies. We present the first community-based study to show an association between nonsyndromal CKD and hearing loss. Study Design: Cross-sectional population-based study to examine the relationship between CKD and age-related hearing loss. Setting & Participants: The Blue Mountains Hearing Study is a survey of age-related hearing loss conducted in 1997-2004; a total of 2,564 participants had audiometric testing and complete renal data. Predictor or Factor: Moderate CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Outcomes: Bilateral hearing loss, defined as average pure-tone threshold >25 dB for measurements at frequencies of 0.5, 1.0, 2.0, and 4.0 kHz. Measurements: Baseline biochemistry tests, including serum creatinine, were performed. Pure-tone audiometry was performed in sound-treated booths. Results: Moderate CKD was present in 513 of 2,564 participants. Of persons with moderate CKD, 279 (54.4%) had measured hearing loss compared with 581 (28.3%) with eGFR <60 mL/min/1.73 m2. Moderate CKD was independently associated with hearing loss (OR, 1.43; 95% CI, 1.10-1.84; P = 0.006) after adjusting for age; sex; noise exposure; education; diabetes, hypertension, and stroke histories; and smoking. Participants with eGFR <45 mL/min/1.73 m2 had the highest prevalence of hearing loss (73%) compared with those with eGFR <90 mL/min/1.73 m2 (19%; multivariate adjusted OR, 2.4 [95% CI, 1.3-4.5]). Analyses were repeated after excluding participants reporting furosemide use (a known ototoxic agent); the association between moderate CKD and hearing loss remained significant (multivariate adjusted OR, 1.40 [95% CI, 1.08-1.83]; P = 0.01). Limitations: The present study is not longitudinal and does not permit causal inference from the observed associations. Conclusions: Moderate CKD per se was associated independently with hearing loss. Recognizing this link could lead to earlier hearing assessment with appropriate interventions to preserve the hearing of patients with CKD. Am J Kidney Dis 00:00-00

AB - Background: Chronic kidney disease (CKD) has long been associated with hearing loss in certain syndromes. Reported evidence to date has come from only small observational studies. We present the first community-based study to show an association between nonsyndromal CKD and hearing loss. Study Design: Cross-sectional population-based study to examine the relationship between CKD and age-related hearing loss. Setting & Participants: The Blue Mountains Hearing Study is a survey of age-related hearing loss conducted in 1997-2004; a total of 2,564 participants had audiometric testing and complete renal data. Predictor or Factor: Moderate CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Outcomes: Bilateral hearing loss, defined as average pure-tone threshold >25 dB for measurements at frequencies of 0.5, 1.0, 2.0, and 4.0 kHz. Measurements: Baseline biochemistry tests, including serum creatinine, were performed. Pure-tone audiometry was performed in sound-treated booths. Results: Moderate CKD was present in 513 of 2,564 participants. Of persons with moderate CKD, 279 (54.4%) had measured hearing loss compared with 581 (28.3%) with eGFR <60 mL/min/1.73 m2. Moderate CKD was independently associated with hearing loss (OR, 1.43; 95% CI, 1.10-1.84; P = 0.006) after adjusting for age; sex; noise exposure; education; diabetes, hypertension, and stroke histories; and smoking. Participants with eGFR <45 mL/min/1.73 m2 had the highest prevalence of hearing loss (73%) compared with those with eGFR <90 mL/min/1.73 m2 (19%; multivariate adjusted OR, 2.4 [95% CI, 1.3-4.5]). Analyses were repeated after excluding participants reporting furosemide use (a known ototoxic agent); the association between moderate CKD and hearing loss remained significant (multivariate adjusted OR, 1.40 [95% CI, 1.08-1.83]; P = 0.01). Limitations: The present study is not longitudinal and does not permit causal inference from the observed associations. Conclusions: Moderate CKD per se was associated independently with hearing loss. Recognizing this link could lead to earlier hearing assessment with appropriate interventions to preserve the hearing of patients with CKD. Am J Kidney Dis 00:00-00

UR - http://www.scopus.com/inward/record.url?scp=77956898285&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2010.05.015

DO - 10.1053/j.ajkd.2010.05.015

M3 - Article

VL - 56

SP - 661

EP - 669

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 4

ER -